Rico Cordeiro O, Bravo González J R, Díaz González M
Instituto de Medicina Tropical Pedro Kouri.
Rev Cubana Med Trop. 1994;46(2):94-8.
The effectiveness or post-license efficacy of the BC antimeningococcal vaccine (VA-MENGOC-BC) was assessed 1 year after the end of the immunization campaign in children aged 0 to 5 years. Occurrence of the disease before and after intervention is described and effectiveness is estimated following the recommendations described by Orenstein et al. We used 2 case definitions to compare results in groups formed following different criteria, according to the employed diagnostic tests. Two formulas are used to assess efficacy: one, estimating the rates among vaccinated and non-vaccinated; and the other one, estimating the ratio of cases per vaccinated population. The increase of the relative annual decrease of the incidence occurring since 1985--a decrease of 10% or less--which in 1990 reached 34.6% should be stressed; the ratio of new cases prevented by the intervention was higher than 75%. Effectiveness or post-license efficacy was close to 90%, independently from the case definition variant or formula employed.
在0至5岁儿童的免疫活动结束1年后，评估了BC群脑膜炎球菌疫苗（VA-MENGOC-BC）的有效性或上市后效力。描述了干预前后疾病的发生情况，并根据奥伦斯坦等人描述的建议估计了有效性。根据所采用的诊断测试，我们使用了2种病例定义来比较按照不同标准形成的组中的结果。使用两个公式来评估效力：一个是估计接种疫苗和未接种疫苗人群中的发病率；另一个是估计每接种疫苗人群中的病例数比例。应强调自1985年以来发病率相对年下降率的增加——下降率为10%或更低——而在1990年达到了34.6%；干预预防的新病例比例高于75%。有效性或上市后效力接近90%，与所采用的病例定义变体或公式无关。
